Pfizer Secures Trademark and Political Breathing Room
Oct/02/2025
Pfizer’s latest trademark filing for 'KATPRIFVI', covering a vast range of therapies from autoimmune disorders to vaccines, coincided with a high-profile policy pivot in Washington. On September 30th, CEO Albert Bourla stood beside Donald Trump to unveil "TrumpRx", a scheme promising steep drug discounts and a pledge to align U.S. prices with those in other developed markets. In exchange for sweeping price concessions and a $70 billion investment in American manufacturing and research, Pfizer secured a reprieve from tariff threats, signalling a détente in the administration’s clash with Big Pharma. Investors welcomed the development: Pfizer’s stock surged more than 10% as political risk appeared to recede, echoing the sharp rebound in the 1990s when healthcare reform fizzled. Although the pharmaceutical sector still lags broader equities, a cooling of regulatory pressure and signs of economic slowdown could make healthcare stocks attractive again. For Pfizer, the pivot comes as it looks to offset falling COVID vaccine revenues with new pipelines, backed by heavy R&D spending and a history of blockbuster launches.
